San José, Costa Rica. February 18, 2021. Biomerics, a leading mid-market medical device contract manufacturer, announced it is doubling its manufacturing footprint in the Zeta Free Trade Zone in Cartago, Costa Rica. Biomerics held a joint groundbreaking ceremony with Zeta and CINDE on Friday, February 12, 2021.
The expansion is via a new greenfield plant adjacent to Biomerics current operations and includes extrusion, injection molding, micro metal processing, and cleanroom assembly process. The new facility construction totaling 110,000 sq. ft. will reflect Biomerics vertically integrated, full-service business model and will include engineering labs, quality inspection labs, controlled environment manufacturing, office space, class 7 clean rooms, packaging, and warehouse facilities.
“The news of Biomerics’ expansion is an excellent example of how the country has been able to position itself internationally as an important player and attractive destination for medical device companies. Medical devices are currently Costa Rica’s main export product, accounting for 32% of the country’s exported goods in 2019. It therefore gives us great pride to know that Biomerics has found a solid, robust platform in Costa Rica for not only growing but also incorporating more sophisticated, high value-added processes to its business,” noted Minister of Foreign Trade Andrés Valenciano.
Finally, he added, “We congratulate Biomerics on its growth and thank them for their vote of confidence in our country and its people. We will keep working in the foreign trade sector on a coherent and consistent policy of foreign trade and foreign direct investment attraction so that increasingly more Costa Ricans can benefit from our insertion in the global economy and take advantage of the development opportunities this offers.”
Biomerics currently employs 175 people at its 50,000 sq. ft. facility focused on extrusion, laser processing, high volume assembly, and packaging. The expansion is in support of active transfer programs with strategic customers and is expected to double its number of Costa Rican employees over the next three years.
"This expansion is in line with our vision to be the leading interventional contract manufacturer," stated Travis Sessions, Biomerics CEO. "Customers have requested that we build a vertically integrated operation in Costa Rica to provide cost-effective high volume manufacturing for the interventional market.”
"We are excited for the value that this expansion brings to our existing customer base in Costa Rica and interventional OEM partners around the globe," stated Chris Richardson, Biomerics Director of Sales and Marketing. "The thriving medical device ecosystem in Costa Rica aligns well with Biomerics’ culture and innovative core."
Jorge Sequeira Picado, CINDE’s Managing Director, commented, “The resilience shown by the life sciences industry in Costa Rica positions us as the ideal destination for the new nearshoring. In point of fact, Biomerics’ investment will permit more vertical integration of its business and help many original medical equipment manufacturers (OEMs) keep their supply chain closer. This sector created a total of 38,248 formal jobs by the end of 2020 and thanks to investments such as that of Biomerics we expect the trend to continue growing this year.”
Construction is expected to be completed by Q4 2021 and will be celebrated with an open house.
Founded in 1993, Biomerics is a mid-market medical device contract manufacturer serving the Interventional Cardiovascular, Gastrointestinal, and Advanced Surgical markets. As a vertically integrated partner, Biomerics supplies 20 of the top 30 medical device OEMs. Biomerics provides engineering development services, technical transfer manufacturing services, and contract manufacturing service for finished medical devices through various locations in the United States and Costa Rica. Biomerics is a leader in biomaterials, injection molding, extrusion, micro metals processing, medical balloons, catheter assembly, and finished packaging. Biomerics operates under certified ISO 13485:2016 quality system and is FDA registered.